LivaNova’s latest vagus nerve stimulation (VNS Therapy) system has received US Food and Drug Administration (FDA) approval for expanded magnetic resonance imaging labelling.
According to a company release, this means that VNS Therapy patients with the latest technology could visit any MRI centre in the USA and have access to more than 90% of scans routinely performed on patients with epilepsy.
Currently, AspireHC and AspireSR models of VNS Therapy technology provide for this expanded MRI access, enabling patients to obtain high-quality MRI scans.
To date, VNS Therapy—a minimally invasive treatment designed to prevent seizures before they start and stop them if they do—has been used by more than 100,000 patients worldwide.
